Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Jade Biosciences announced positive interim Phase 1 trial results of JADE101, a novel anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN). Results demonstrated approximately 70% sustained IgA reduction at 12 weeks after a single dose, with potential for every 12-week subcutaneous maintenance dosing. JADE101 showed faster, deeper,…